Eckert+Ziegler: Pure Player in the Future 30 Billion USD Market for Targeted Radiotherapies!
Reading Time: 2 minutes
Eckert+Ziegler is, following the separation from Pentixapharm, a pure provider of medical isotopes for targeted radiotherapies. These include, for example, Gallium-68 (diagnostic isotope), Lutetium-177, Actinium-225, and Yttrium-90. These isotopes help diagnose cancer cells and destroy them with minimal damage to the surrounding tissue. The market for these therapies is expected to explode to 30 billion USD by 2030, with major pharmaceutical companies like Novartis, BMS, and Eli Lilly increasingly aggressively entering this market. At the end...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
